Synthesis of thymosin .alpha..sub.1
AssigneeHoffmann-La Roche Inc.
InventorSu-Sun Wang
Life of this patent
Estimating the term…
Abstract
Thymosin .alpha..sub.1, was chemically synthesized by the fragment condensation of the protected amino terminal tetradecapeptide with the protected carboxyl terminal tetradecapeptide and by solid phase peptide synthesis. Thymosin .alpha..sub.1 is active as an agent which affects regulation, differentiation and function of thymus dependent lymphocytes (T cells).
Claims10
Ac-Se r(R.sup.1)-Asp(OR.sup.2)-Ala-Ala-Val-Asp(OR.sup.2)-Thr(R.sup.3)-Ser(R.sup.1 )-Ser(R.sup.1)-Glu(OR.sup.4)-Ile-Thr(R.sup.3)-Thr(R.sup.3)-Lys(R.sup.5)-Asp (OR.sup.2)-Leu-Lys(R.sup.5)-Glu(OR.sup.4)-Lys(R.sup.5)-Lys(R.sup.5)-Glu(OR. sup.4)-Val-Val-Glu(OR.sup.4)-Glu(OR.sup.4)-Ala-Glu(OR.sup.4)-Asn-OR.sup.6 wherein Ac is acetyl;
- R.sup.1 is a conventional protecting group for the hydroxyl group of the serine residue;
- R.sup.2 is a conventional carboxyl protecting group;
- R.sup.3 is a conventional protecting group for the hydroxyl group of threonine;
- R.sup.4 is a conventional carboxyl protecting group;
- R.sup.5 is a conventional .omega.-amino protecting group;
- and R.sup.6 is a conventional carboxyl protecting group.
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys and pharmaceutically acceptable salts thereof.
Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn and pharmaceutically acceptable salts thereof.
Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn and pharmaceutically acceptable salts thereof.
Glu-Val-Val-Glu-Glu-Ala-Glu-Asn and pharmaceutically acceptable salts thereof.
H-Asp( OBzl)-Leu-Lys(Z)-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu(OB zl)-Ala-Glu(OBzl)-Asn-OBzl and the trifluoroacetic acid salt thereof, wherein Bzl is benzyl and Z is benzyloxycarbonyl.
Ac-Ser(Bzl)-Asp(OBzl)-Ala-Ala-Val-Asp(OBzl)-Thr (Bzl)-Ser(Bzl)-Ser(Bzl)-Glu-(OBzl)-Ile-Thr(Bzl)-Thr(Bzl)-Lys(Z)-OH wherein Ac is acetyl, Bzl is benzyl and Z is benzyloxycarbonyl.
Ac-Ser(R.sup.1)-Asp(OR.sup.2)-Ala-Ala-Val(OR.sup.2)-A sp(OR.sup.2)-Thr(R.sup.3)-Ser(R.sup.1)-Ser(R.sup.1)-Glu (OR.sup.4)-Ile-Thr(R.sup.3)-Thr(R.sup.3)-Lys(R.sup.5)-Asp(OR.sup.2)-Leu-Ly s(R.sup.5)-Glu(OR.sup.4)-Lys(R.sup.5)-Lys (R.sup.5)-Glu(OR.sup.4)-Val-Val-Glu(OR.sup.4)-Glu(OR.sup.4)-Ala-Glu(OR.sup .4)-Asp-(CONH-CH(C.sub.6 H.sub.5)- ##STR2## Resin)-OR.sup.2 wherein Ac is acetyl;
- R.sup.1 is a conventional protecting group for the hydroxyl group of the serine residue;
- R.sup.2 is a conventional carboxyl protecting group;
- R.sup.3 is a conventional protecting group for the hydroxyl group of threonine;
- R.sup.4 is a conventional carboxyl protecting group;
- R.sup.5 is a conventional .omega.-amino protecting group and R.sup.6 is a conventional carboxyl protecting group.
Dependencies are inferred from the claim text.